Immuno-Oncology and Cell Therapy

Explore By Subject Area

Serving the IO and Cell Therapy Community

Lead Editorial

Could In Vivo CAR-T Cell Therapy Replace Ex Vivo?

Could In Vivo CAR-T Cell Therapy Replace Ex Vivo?

Dr Adrian Bot, Capstan Therapeutics, tells us how in vivo CAR-T cell therapy, both through viral and non-viral vectors, could provide patients with a less toxic and more accessible alternative to traditionally manufactured ex vivo CAR-T.

Featured Editorial

IO360º Convenes Technology and Solution Providers to Address Key Capabilities to Advance IO Drug Development

MSK on Adding ADCs to Checkpoint Blockade for Bladder Cancer Patients

Shining a Light on the Immune System to Inform Medicine Development at GSK

Immuno-Oncology 360º Announces 2026 Featured Speakers and Key Topics for the 12th Annual Meeting in Boston

More Related Content

Editorial

Conference Forum Joins Fierce Life Sciences

Conference Forum Joins Fierce Life Sciences

Developing Nonactivated CAR T Therapy for Greater Persistence, Reduced Exhaustion and Enhanced In Vivo Expansion

Developing Nonactivated CAR T Therapy for Greater Persistence, Reduced Exhaustion and Enhanced In Vivo Expansion

Whole-Body Molecular Imaging’s Impact on Understanding Tumor Response and Advancing Immuno-Oncology (IO) Drug Development

Whole-Body Molecular Imaging’s Impact on Understanding Tumor Response and Advancing Immuno-Oncology (IO) Drug Development

Going After Immune Resistance and Metastases in Cancer Using RNA-Based Therapeutics

Going After Immune Resistance and Metastases in Cancer Using RNA-Based Therapeutics

Staying Passionate about IO’s Potential and Investing in Biotechs Addressing IO’s Toughest Challenges

Staying Passionate about IO’s Potential and Investing in Biotechs Addressing IO’s Toughest Challenges

GSK’s Head of Precision Medicine on Biomarker Focus and the Use of Next-Generation Technologies

GSK’s Head of Precision Medicine on Biomarker Focus and the Use of Next-Generation Technologies

T Cell Engagers, Moving Beyond Pembrolizumab, and Medicine Development for Future Patients, with Roche's Ashley Lakner

T Cell Engagers, Moving Beyond Pembrolizumab, and Medicine Development for Future Patients, with Roche's Ashley Lakner

Pediatric Oncology’s Changing Regulatory Landscape and How to Navigate It

Pediatric Oncology’s Changing Regulatory Landscape and How to Navigate It

How Merck Research Labs Is Evolving its Global Clinical Supply to Meet the Demands of Newer Modalities

How Merck Research Labs Is Evolving its Global Clinical Supply to Meet the Demands of Newer Modalities

Leveraging a US-Chinese Biotech Collaboration to Develop a PD-1/VEGF Bispecific Antibody

Leveraging a US-Chinese Biotech Collaboration to Develop a PD-1/VEGF Bispecific Antibody

Immuno-Oncology 360° 2025 Recap

Immuno-Oncology 360° 2025 Recap

Developing Checkpoint Inhibitors for Patients Who Don’t Respond to PD-1/CTLA-4

Developing Checkpoint Inhibitors for Patients Who Don’t Respond to PD-1/CTLA-4

Breaking Down Silos and Applying Automation to Turn Imaging Analysis on Its Head

Breaking Down Silos and Applying Automation to Turn Imaging Analysis on Its Head

Women Leadership in Immuno-Oncology Annual Profile Series: 2025 Edition

A Systemic Approach to Oncolytic Viruses for Treating Solid Tumors

A Systemic Approach to Oncolytic Viruses for Treating Solid Tumors

AbbVie’s Head of Oncology Precision Medicine on the Exciting Developments in Immuno-Oncology

AbbVie’s Head of Oncology Precision Medicine on the Exciting Developments in Immuno-Oncology

How Immatics’ VP of Late-Stage Development Navigating the Transition from Early Development for a TCR-T Therapy

How Immatics’ VP of Late-Stage Development Navigating the Transition from Early Development for a TCR-T Therapy

How AstraZeneca Approaches Finding New Treatments for Patients with Multiple Myeloma

How AstraZeneca Approaches Finding New Treatments for Patients with Multiple Myeloma

Making Cell and Gene Therapy Accessible for Medicaid Enrollees: White Paper

Making Cell and Gene Therapy Accessible for Medicaid Enrollees: White Paper

Harnessing the Power of Cytokines with a Conditionally Active Agent

Harnessing the Power of Cytokines with a Conditionally Active Agent

Creating In Vivo Protein Factories at Be Bio for a New Class of Biologics

Creating In Vivo Protein Factories at Be Bio for a New Class of Biologics

Coherus Chief Development Officer on Next Steps in Toripalimab Drug Development

Coherus Chief Development Officer on Next Steps in Toripalimab Drug Development

Morgan Stanley’s Co-Head of Healthcare Equity Capital Markets on What IO Biotechs Can Expect in 2025

Morgan Stanley’s Co-Head of Healthcare Equity Capital Markets on What IO Biotechs Can Expect in 2025

The Current State of the IO Fundraising Landscape from a Long-Time Biotech Investor

The Current State of the IO Fundraising Landscape from a Long-Time Biotech Investor

The State of Cell Therapy Manufacturing with the Rise of Approved Products

The State of Cell Therapy Manufacturing with the Rise of Approved Products

The Conference Forum Sees Record Growth in Attendees Across 2024 Events, Bringing Together Leaders in Medicine Development

The Conference Forum Sees Record Growth in Attendees Across 2024 Events, Bringing Together Leaders in Medicine Development

Improving CAR T Therapies with Better Patient Access at Novartis

Improving CAR T Therapies with Better Patient Access at Novartis

How Circulating Tumor DNA is Being Evaluated as a Potential Endpoint for Immuno-Oncology

How Circulating Tumor DNA is Being Evaluated as a Potential Endpoint for Immuno-Oncology

Key Skills and Career Moves on the Journey to Becoming a CEO, with Fred Hassan

Key Skills and Career Moves on the Journey to Becoming a CEO, with Fred Hassan

Why Some People Respond to IO, and Others Don’t

Why Some People Respond to IO, and Others Don’t

What Immuno-Oncologists Need to Know About Radiopharmaceuticals

What Immuno-Oncologists Need to Know About Radiopharmaceuticals

Transforming Autoimmune Patient Outcomes with CAR T

Transforming Autoimmune Patient Outcomes with CAR T

Practical Considerations of Response Assessment in Neuro-Oncology 2.0 for Clinical Trials

Practical Considerations of Response Assessment in Neuro-Oncology 2.0 for Clinical Trials

Unlocking Precision Medicine, Tumor Heterogeneity and Patient Monitoring with Advances in Imaging

Unlocking Precision Medicine, Tumor Heterogeneity and Patient Monitoring with Advances in Imaging

Developing a Molecule to Help Patients Respond to Immunotherapy

Developing a Molecule to Help Patients Respond to Immunotherapy

A New Approach to Cancer Vaccines, With a Focus on T Cells

A New Approach to Cancer Vaccines, With a Focus on T Cells

IO360º 2024 – Utilization of IO Agents in Adjuvant Disease and Update on Adjuvant Vaccine Studies

IO360º 2024 – Utilization of IO Agents in Adjuvant Disease and Update on Adjuvant Vaccine Studies

Providing IO Options for Breast Cancer Patients

Providing IO Options for Breast Cancer Patients

Dr Roy Baynes on Strategy Development for Keytruda

Dr Roy Baynes on Strategy Development for Keytruda

Embracing the Role of the Chief Medical Officer at Legend Biotech

Embracing the Role of the Chief Medical Officer at Legend Biotech

How Circular RNA is Enabling In Vivo CAR Delivery and Reducing Patient Treatment Burden

How Circular RNA is Enabling In Vivo CAR Delivery and Reducing Patient Treatment Burden

RNA Therapeutics for Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer

RNA Therapeutics for Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer

Moffitt Cancer Center CEO Dr Patrick Hwu on CAR T, TILs and Tracking Patient Outcomes

Moffitt Cancer Center CEO Dr Patrick Hwu on CAR T, TILs and Tracking Patient Outcomes

The Role of Generative AI in Making Better Immuno-Oncology Therapeutics

The Role of Generative AI in Making Better Immuno-Oncology Therapeutics

Pushing IO and Cell Therapy Further at Astellas

Pushing IO and Cell Therapy Further at Astellas

Reporting on the Latest Advancements and Data in IO: Immuno-Oncology 360° 2024 Recap

Reporting on the Latest Advancements and Data in IO: Immuno-Oncology 360° 2024 Recap

When Immunotherapy Offers the Chance for Life and Family After Cancer Diagnosis

When Immunotherapy Offers the Chance for Life and Family After Cancer Diagnosis

Getting Cell Therapies into Solid Tumors and Avoiding Immune Suppression

Getting Cell Therapies into Solid Tumors and Avoiding Immune Suppression

The First-Time CEO Using a New Paradigm to Attack Metastatic Cancer

The First-Time CEO Using a New Paradigm to Attack Metastatic Cancer

The Biotech Analyst Helping Immuno-Oncology Investors Make Better Decisions

The Biotech Analyst Helping Immuno-Oncology Investors Make Better Decisions

How to Make Tumors More Targetable, Using the Tumor Microenvironment

How to Make Tumors More Targetable, Using the Tumor Microenvironment

Carl June and Daniel Chen on the Future of CAR-T, Cell Therapy, T-Cell Engagers and Synthetic Immunity

Carl June and Daniel Chen on the Future of CAR-T, Cell Therapy, T-Cell Engagers and Synthetic Immunity

Using Innate Immunity to Create a New Way of Going After Cancer

Using Innate Immunity to Create a New Way of Going After Cancer

Localizing Immuno-Oncology: The Right Therapy, to the Right Tumor

Localizing Immuno-Oncology: The Right Therapy, to the Right Tumor

The Regulatory Affairs Leader Helping to Advance Novel Therapies and Establish New Surrogate Endpoints

The Regulatory Affairs Leader Helping to Advance Novel Therapies and Establish New Surrogate Endpoints

Giving New Hope to Myeloma Patients and Working on the Next Generation of Cell Therapies

Giving New Hope to Myeloma Patients and Working on the Next Generation of Cell Therapies

Developing New Checkpoint Inhibitors for Patients and Finding Inspiration from Immunotherapy

Developing New Checkpoint Inhibitors for Patients and Finding Inspiration from Immunotherapy

Building a Biotech from a Technology That Turns Target Identification on its Head

Building a Biotech from a Technology That Turns Target Identification on its Head

Going from R&D to Commercial to Have a Different Impact on Patient Lives

Going from R&D to Commercial to Have a Different Impact on Patient Lives

Blocking GDF-15 to Conquer Immunosupression and Enhance Treatment Efficacy

Blocking GDF-15 to Conquer Immunosupression and Enhance Treatment Efficacy

Dr Carolyn Bertozzi Shares Her Award-Winning Work in IO and Her Hope for Greater Diversity in the Field

Dr Carolyn Bertozzi Shares Her Award-Winning Work in IO and Her Hope for Greater Diversity in the Field

Directing AstraZeneca's Oncology Strategies

Directing AstraZeneca's Oncology Strategies

UPenn's Dr Bruce Levine on Advancements in Cell Therapy Manufacturing

UPenn's Dr Bruce Levine on Advancements in Cell Therapy Manufacturing

How the NYU Genome Center is Making Better Cell Therapies

How the NYU Genome Center is Making Better Cell Therapies

Developing MSK's First Gene Transfer Clinic, Expediting Cell Therapy

Developing MSK's First Gene Transfer Clinic, Expediting Cell Therapy

MGH Cancer Center Breaks Down the T Cell to Better Understand Immuno-Oncology

MGH Cancer Center Breaks Down the T Cell to Better Understand Immuno-Oncology

New Approaches to Treat Brain Cancers Out of City of Hope

New Approaches to Treat Brain Cancers Out of City of Hope

Leading Immune Checkpoint Therapy Trials in NSCLC, at MD Anderson

Leading Immune Checkpoint Therapy Trials in NSCLC, at MD Anderson

Merck's Mission for More Effective Breast Cancer Immunotherapy Treatments

Merck's Mission for More Effective Breast Cancer Immunotherapy Treatments

BMS on Managing IO Operations and Sparking Joy for Science in Young People

BMS on Managing IO Operations and Sparking Joy for Science in Young People

Combining Natural Killer Cells and Synthetic Biology to Fight Solid Tumor Cancers

Combining Natural Killer Cells and Synthetic Biology to Fight Solid Tumor Cancers

Takeda’s Approach to Translational Medicine in Immuno-Oncology

Takeda’s Approach to Translational Medicine in Immuno-Oncology

Archive Highlight: How Genomics Is Advancing the Next Generation of IO at the Cleveland Clinic

Archive Highlight: How Genomics Is Advancing the Next Generation of IO at the Cleveland Clinic

Dr Arie Belldegrun on Staying Ahead of the Scientific Curve

Dr Arie Belldegrun on Staying Ahead of the Scientific Curve

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.

First Name*

Last Name*

Email*

Areas of Interest*